TABLE 4.

Statin Treatment Patterns in P+ and P+ Augmented with LRx

Proportion of Patients, n (%)	P+ Only (N= 965,785)	P+ Augmented with LRx (N = 965,785)	P Value
Low-intensity statin (at index)	118,037 (12.2)	117,540 (12.2)	0.275
Moderate-intensity statin (at index)	602,158 (62.3)	601,474 (62.3)	0.310
High-intensity statin (at index)	233,622 (24.2)	235,170 (24.4)	0.009
With dose increase	74,058 (7.7)	78,903 (8.2)	< 0.001
With dose decrease	35,130 (3.6)	39,597 (4.1)	< 0.001
With intensity escalation	41,837 (4.3)	44,317 (4.6)	< 0.001
Low to moderate intensity	14,142 (1.5)	14,845 (1.5)	< 0.001
Moderate to high intensity	25,727 (2.7)	27,348 (2.8)	< 0.001
Low to high intensity	1,968 (0.2)	2,124 (0.2)	0.015
With intensity reduction	19,185 (2.0)	21,360 (2.2)	< 0.001
Moderate to low intensity	7,295 (0.8)	8,042 (0.8)	< 0.001
High to moderate intensity	10,852 (1.1)	12,133 (1.3)	< 0.001
High to low intensity	1,038 (0.1)	1,185 (0.1)	0.002
Started on monotherapy	926,716 (96.0)	924,157 (95.7)	< 0.001
Augmented to combination therapy	72,885 (7.9)	80,281 (8.7)	< 0.001
Started on combination therapy	39,069 (4.0)	41,628 (4.3)	< 0.001
Augmented from combination therapy	4,620 (11.8)	5,583 (13.4)	< 0.001
Discontinued (≥ 90-day gap)	276,021 (28.6)	254,460 (26.3)	< 0.001
Reinitiated after ≥ 90-day gap	38,786 (14.1)	38,402 (15.1)	< 0.001
Discontinued (≥ 60-day gap)	351,184 (36.4)	326,533 (33.8)	< 0.001
Reinitiated after ≥ 60-day gap	194,032 (55.3)	183,318 (56.1)	< 0.001

Note: Because of the unavailability of published statin dose equivalents for ezetimibe, dose intensity was unavailable for approximately 1.2% of patients on ezetimibe monotherapy at index.

LRx = IMS longitudinal pharmacy point-of-sale prescription claims database; P+ = PharMetrics Plus claims database.